Hikal Ltd - HIKAL Share Price

Sector: Pharmaceuticals | ISIN: INE475B01022
₹ 284.90 (-0.04%) icon22 Feb, 2024, 12:00:00 AM
Open
₹ 285.10
Prev. Close
₹ 285.00
Turnover(lac)
₹ 0.00
Day's High
₹ 288.30
Day's Low
₹ 281.40
52 Wk High
₹ 329.00
52 Wk Low
₹ 250.10
Book Value
₹ 94.82
Face Value
₹ 2.00
Mkt. Cap (Cr.)
₹ 3,512.84
P/E
48.93
EPS
5.82
Div. Yield
0.42

Hikal Ltd Stock View

info icon
Edit Image
STRONG BUY
Target | 14 Feb, 2024 330 (15.79%)

Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activit... Read More

Hikal Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 2/22/2024 12:00:00 AM

    ₹ 284.9 -0.10 -0.04
  • Open
  • ₹ 285.1
  • Prev. Close
  • ₹ 285
  • Turnover(Lac.)
  • ₹ 368
  • Day's High
  • ₹ 288.3
  • Day's Low
  • ₹ 281.4
  • 52 Week's High
  • ₹ 329
  • 52 Week's Low
  • ₹ 250.1
  • Book Value
  • ₹ 94.82
  • Face Value
  • ₹ 2
  • Mkt Cap (₹ Cr.)
  • 3,512.84
  • P/E
  • 48.93
  • EPS
  • 5.82
  • Divi. Yield
  • 0.42

Hikal Ltd Corporate Actions

08 Feb , 2024

12:00 AM

Dividend

Dividend amount: 0.6
Announcement date: 08 Feb , 2024

View Details

01 Feb , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

01 Feb , 2024

12:00 AM

11 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

25 Oct , 2023

12:00 AM

25 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

31 Aug , 2023

12:00 AM

AGM

Announcement date: 31 Aug , 2023

View Details

29 May , 2023

12:00 AM

Dividend

Dividend amount: 0.6
Announcement date: 29 May , 2023

View Details

16 Aug , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

01 Aug , 2023

12:00 AM

01 Aug , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

22 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

01 Sep , 2023

12:00 AM

BookCloser

View Details

Hikal Ltd News and Update

Image not found
  • 9 hours ago |
  • 12:06 AM

Think and Learn Pvt Ltd, the company that owns Byju's, is accused of breaking India's foreign exchange rules

Image not found
Image not found
  • IIFL News Service |
  • 16 February, 2024 |
  • 11:57 PM
Article Image

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Hikal Ltd SHAREHOLDING SNAPSHOT
22 February , 2024 | 10:46 PM

PROMOTER - TOTAL68.85%

Indian: 68.85%

Foreign: 0%

NON-PROMOTER - TOTAL 31.15%

Institutions: 9.29%

Non-Institutions: 21.86%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Hikal Ltd FINANCIALS

Hikal Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Hikal Ltd

  • Baba Kalyani
  • Non-Exec & Non-Independent Dir
  • Jai Hiremath
  • Executive Chairman
  • Sameer Hiremath
  • Managing Director
  • Kannan Unni
  • Non-Exec. & Independent Dir.
  • Sugandha Hiremath
  • Non-Exec & Non-Independent Dir
  • Prakash V Mehta
  • Non-Exec. & Independent Dir.
  • Amit B Kalyani
  • Non-Exec & Non-Independent Dir
  • Ranjit Shahani
  • Non-Exec. & Independent Dir.
  • Shivani Bhasin Sachdeva
  • Non-Exec. & Independent Dir.
  • Rajasekhar Reddy
  • Company Sec. & Compli. Officer
  • Shrikrishna K. Adivarekar
  • Independent Director
  • Berjis Minoo Desai
  • Independent Director
  • V R Kaundinya
  • Independent Director

Summary

Hikal Limited, incorporated on July 08th, 1988, has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals, crop protection, animal health, biocides, and specialty chemicals. The Company is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. Presently, it is operating in the crop protection and pharmaceuticals space.The Company has 5 manufacturing facilities across three states in India. It supply products to customers across the globe in the US, Japan, Europe, Canada, South East Asia, LATAM, India and RoW. Apart from this, it specialize in manufacturing APIs and intermediates in pharmaceutical division. Within pharmaceutical division, it offer human health and animal health products.Hikal commenced its first project in 1991 at its first greenfield site at M.I.D.C., Mahad with the manufacture of intermediates for agrochemical industry. It also bagged first big contract with Hoechst. During 1996, Company came with public issue to part finance the expansion project of Thiabendazol. It achieved another milestone when Merck & Co., USA chose Hikal as a partner to outsource Thiabendazole (TBZ, a fungicide). Since the capacity at Mahad was inadequate, Hikal built second greenfield site, a state-of-the-art manufacturing facility at Taloja in 1997. The Company has been accorded Export House status by the Government of India. It set up a new... Read More


Reports by Hikal Ltd


Reports by Hikal Ltd

Company FAQ

No Record Found